Action Gsk - GSK

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

1 405,00

Prix Achat

1 406,00

Prix Vente

1 406,50

Volume échangé

13 745 946

1 399,50 Fourchette du Jour 1 410,50

1 282,50 Plage de 52 semaines 1 820,00

Cap du marché

58,239B

Clôture Veille

1 402,00

Ouverture

1 404,00

Dernière Transaction

1404.5

(O)

Dernière heure de transaction

Volume financier

193 098 568p

VWAP

1 404,7674

Volume moyen (3 m)

7 581 468

Actions en circulation

4 145 132 579

Rendement du Dividende

4.27%

Ratio Cours sur Bénéfices

11,83

Bénéfice par action (BPA)

1,19

Chiffre d'affairess

30,33B

Bénéfice net

4,93B

Secteur

Pharmaceutical Preparations

Industrie

Pharmaceutical Preparations

Site Web

www.gsk.com

Siège social

London, Gbr

Fondé

Gsk Plc est coté dans le secteur Pharmaceutical Preparations de la London Stock Exchange avec le ticker GSK. Le dernier cours de clôture d'Gsk était de 1 402,00p. Au cours de la dernière année, les actions de Gsk ont été négociées dans une fourchette de prix de 1 282,50p à 1 820,00p.

Gsk compte actuellement 4 145 132 579 actions en circulation. La capitalisation boursière d'Gsk est de £58,11 milliard. Gsk a un ratio cours/bénéfice (ratio PE) de 11.83.

GSK applications for sinus disease treatment accepted for review

GSK PLC on Tuesday said applications for its treatment for a type of asthma and chronic rhinosinusitis with nasal pol ...

GSK PLC Depemokimab dual filing in China and Japan

GSK PLC 28 January 2025 Issued: 28 January 2025 London UK Depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP · If approved...

GSK PLC EMA accepts two submissions for depemokimab

GSK PLC 28 January 2025 Issued: 28 January 2025 London UK Depemokimab accepted for review by the European Medicines Agency for use in asthma with type 2 inflammation and CRSwNP · If...

GSK and University of Oxford researchers to create cancer vaccine

Pharmaceutical firm GSK PLC and the University of Oxford are creating a new cancer vaccine to prevent the disease fro ...

GSK shingles treatment application accepted for review in Europe

GSK PLC on Monday said the European Medicines Agency accepted for review its application for an alternative treatment ...

GSK PLC EMA accept review Shingrix syringe presentation

GSK PLC 27 January 2025 Issued: 27 January 2025, London UK GSK's Shingrix new prefilled syringe presentation accepted for review by European Medicines Agency · If approved, the new...

GSK gets EU nod for expanded use of Jemperli in endometrial cancer

GSK PLC on Monday said the European Commission has expanded approval for its drug Jemperli, in combination with chemo ...

GSK applications for sinus disease treatment accepted for review

GSK PLC on Tuesday said applications for its treatment for a type of asthma and chronic rhinosinusitis with nasal pol ...

GSK PLC Depemokimab dual filing in China and Japan

GSK PLC 28 January 2025 Issued: 28 January 2025 London UK Depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP · If approved...

GSK PLC EMA accepts two submissions for depemokimab

GSK PLC 28 January 2025 Issued: 28 January 2025 London UK Depemokimab accepted for review by the European Medicines Agency for use in asthma with type 2 inflammation and CRSwNP · If...

GSK and University of Oxford researchers to create cancer vaccine

Pharmaceutical firm GSK PLC and the University of Oxford are creating a new cancer vaccine to prevent the disease fro ...

GSK shingles treatment application accepted for review in Europe

GSK PLC on Monday said the European Medicines Agency accepted for review its application for an alternative treatment ...

GSK PLC EMA accept review Shingrix syringe presentation

GSK PLC 27 January 2025 Issued: 27 January 2025, London UK GSK's Shingrix new prefilled syringe presentation accepted for review by European Medicines Agency · If approved, the new...

GSK gets EU nod for expanded use of Jemperli in endometrial cancer

GSK PLC on Monday said the European Commission has expanded approval for its drug Jemperli, in combination with chemo ...

GSK PLC Jemperli expanded approval in the EU

GSK PLC 20 January 2025 Issued: 20 January 2025, London UK European Commission expands Jemperli (dostarlimab) plus chemotherapy approval to all adult patients with primary advanced or...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	40	2.9304029304	1365	1416	1353	8729313	1393.3486865	DE
4	41.5	3.0436376971	1363.5	1416	1289	7004837	1360.73495589	DE
12	9	0.644699140401	1396	1416	1282.5	7581468	1345.97470872	DE
26	-131	-8.52864583333	1536	1678	1282.5	7620240	1447.10521048	DE
52	-130	-8.46905537459	1535	1820	1282.5	7787768	1545.16610754	DE
156	-266.2	-15.9286740067	1671.2	1824.4	1282.5	8542991	1518.3052275	DE
260	-388	-21.6397099833	1793	1847	1190.8	8758548	1499.54491501	DE

GSK - Frequently Asked Questions (FAQ)

What is the current Gsk share price?

The current share price of Gsk is 1 405,00p

How many Gsk shares are in issue?

Gsk has 4 145 132 579 shares in issue

What is the market cap of Gsk?

The market capitalisation of Gsk is GBP 58,11B

What is the 1 year trading range for Gsk share price?

Gsk has traded in the range of 1 282,50p to 1 820,00p during the past year

What is the PE ratio of Gsk?

The price to earnings ratio of Gsk is 11,83

What is the cash to sales ratio of Gsk?

The cash to sales ratio of Gsk is 1,92

What is the reporting currency for Gsk?

Gsk reports financial results in GBP

What is the latest annual turnover for Gsk?

The latest annual turnover of Gsk is GBP 30,33B

What is the latest annual profit for Gsk?

The latest annual profit of Gsk is GBP 4,93B

What is the registered address of Gsk?

The registered address for Gsk is 79 NEW OXFORD STREET, LONDON, WC1A 1DG

What is the Gsk website address?

The website address for Gsk is www.gsk.com

Which industry sector does Gsk operate in?

Gsk operates in the PHARMACEUTICAL PREPARATIONS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
AIQAiq Limited	4,00p (33,33%)	37,88k
INSPInspirit Energy Holdings Plc	0,0036p (28,57%)	1,43B
ALKAlkemy Capital Investments Plc	175,00p (27,27%)	176,27k
KNBKanabo Group Plc	1,00p (25,00%)	461,04k
TCFTheracryf Plc	1,125p (25,00%)	6,72M
MET1Metals One Plc	0,275p (-35,29%)	16,2M
PPSProton Motor Power Systems Plc	0,175p (-22,22%)	848,7k
SYMESupply@me Capital Plc	0,0025p (-19,35%)	372,49M
CGNRConroy Gold & Natural Resources Plc	2,15p (-18,87%)	739,53k
ONCOncimmune Holdings Plc	10,40p (-16,47%)	1,19M
INSPInspirit Energy Holdings Plc	0,0036p (28,57%)	1,43B
NTVONativo Resources Plc	0,0018p (-5,26%)	1,41B
MSMNMosman Oil And Gas Limited	0,041p (10,81%)	1,22B
TRPTower Resources Plc	0,0295p (0,00%)	691,76M
SYMESupply@me Capital Plc	0,0025p (-19,35%)	372,49M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Gsk Plc (GSK)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Gsk Plc

GSK Dernières nouvelles

GSK applications for sinus disease treatment accepted for review

GSK PLC Depemokimab dual filing in China and Japan

GSK PLC EMA accepts two submissions for depemokimab

GSK and University of Oxford researchers to create cancer vaccine

GSK shingles treatment application accepted for review in Europe

GSK PLC EMA accept review Shingrix syringe presentation

GSK gets EU nod for expanded use of Jemperli in endometrial cancer

GSK applications for sinus disease treatment accepted for review

GSK PLC Depemokimab dual filing in China and Japan

GSK PLC EMA accepts two submissions for depemokimab

GSK and University of Oxford researchers to create cancer vaccine

GSK shingles treatment application accepted for review in Europe

GSK PLC EMA accept review Shingrix syringe presentation

GSK gets EU nod for expanded use of Jemperli in endometrial cancer

GSK PLC Jemperli expanded approval in the EU

GSK - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Gsk Plc (GSK) Cours

Gsk Plc (GSK)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Gsk Plc

GSK Dernières nouvelles

GSK - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités